|
|
| | Secukinumab Basic information |
| Product Name: | Secukinumab | | Synonyms: | Secukinumab;Research Grade Secukinumab(DHH28802);AIN 457;AIN457;AIN-457;Secukinumab (anti-IL-17A) | | CAS: | 1229022-83-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Secukinumab Structure]() |
| | Secukinumab Chemical Properties |
| | Secukinumab Usage And Synthesis |
| Clinical Use | Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis | | Drug interactions | Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | | Metabolism | The majority of IgG elimination occurs via intracellular
catabolism, following fluid-phase or receptor mediated
endocytosis. |
| | Secukinumab Preparation Products And Raw materials |
|